Skip to main content
. 2018 Oct;24(10):10.18553/jmcp.2018.24.10.952. doi: 10.18553/jmcp.2018.24.10.952

Table 3.

Baseline Characteristics of Etanercept Biosimilar Switching Studies48-50

Author (Year) Design Biosimilar Product Indication Switched Population Baseline ADA n/N (%) Follow-up (Weeks)
Double-blinded studies
  Griffiths et al. (2017)48 MC PRO RCT Erelzi PsO 100a
96b 		- 40
  Gerdes et al. (2017)49 MC PRO RCT Erelzi PsO 196c - 18
Open-label studies
  Emery et al. (2017)50 MC PRO OBS Brenzys RA 119 48

aPatients receiving GP2015 for period 1 then switched to etanercept→GP2015→etanercept, which continued into extension.

bPatients receiving etanercept for period 1 then switched to GP2015→etanercept→GP2015, which continued into extension.

cIncludes patients from Griffiths et al. (2017)48 who were either switched from a reference to biosimilar or biosimilar to reference product.

ADA = antidrug antibody; MC = multicenter; OBS = observational; PRO = prospective; PsO = psoriasis; RA = rheumatoid arthritis; RCT = randomized controlled trial.